MicroPort® NeuroTech Hosts Intracranial Vascular Endovascular Repair Summit

Shanghai, China – On April 20, MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech") hosted Intracranial Vascular Endovascular Repair Summit in Shanghai and invited several neuro-interventional experts to share opinion in WILLIS® Intracranial Stent Graft System ("WILLIS®") by lectures and case studies.
In the summit, Professor Minghua Li of Shanghai Sixth People's Hospital delivered the opening speech. Professor Minghua Li is the inventor of WILLIS®. Afterwards, Professor Zhiyong Xie of MicroPort® NeuroTech shared the development of WILLIS® to enhance the attendees' understanding in the device. Researched and developed independently by MicroPort® NeuroTech, WILLIS® is the first stent graft system indicated for the treatment of intracranial aneurysms that has gained market approval in China. It is also the first medical device to achieve complete vascular reconstruction in China. WILLIS® vascular reconstruction achieves complete occlusion, and unlike traditional treatment using stent-assisted coil embolization, WILLIS® effectively shunts the blood flow and keeps it off of the aneurysm wall. At the same time, Director Yueqi Zhu of Shanghai Sixth People's Hospital gave a lecture on stent graft systems, covering its R&D, indications, and clinical application.
One of the highlights in the summit is that several physicians shared their clinical experience in using WILLIS®. For instance, Director Sheng Guan of the First Affiliated Hospital of Zhengzhou University lectured on WILLIS®'s indications based on the hemodynamics of aneurysmal neck. Director Xiaodong Xie of West China Hospital of Sichuan University and Director Jieqing Wan of Renji Hospital of Shanghai Jiaotong University School of Medicine respectively shared their clinical experience in using WILLIS®. Director Chun Fang of Tongji University of Tongji Hospital explained different types and solutions of cerebrovascular endovascular exclusion and he spoke highly of the performance of WILLIS®. Afterwards, around 10 physicians separately analyzed clinical cases of WILLIS®.
During the summit, experts had hot discussions regarding indications and techniques of WILLIS®. The excellent performance of WILLIS® won recognition of all the physicians in attendance. Zhiyong Xie, President of MicroPort® NeuroTech, said: "We have been hosting such summit for several years, by which we aim to build a platform for academic exchange and medical education, to jointly promote the development of cerebrovascular endovascular exclusion techniques."